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Introduction
Epithelial–mesenchymal transition (EMT) converts polarized 
epithelial cells to motile mesenchymal cells (Hay, 2005). EMT 
operates during embryonic cell layer movements and tumor cell 
invasiveness (Huber et al., 2005). During EMT, the epithelial 
proteins E-cadherin and zonula occludens 1 (ZO-1) are down-
regulated, and the mesenchymal proteins vimentin, α-smooth 
muscle actin, and fi  bronectin are up-regulated.
Receptor tyrosine kinase, Wnt, Notch, and TGF-β path-
ways trigger EMT (Huber et al., 2005). TGF-β binds to re ceptor 
serine/threonine kinases, which activate intracellular Smad 
and other signaling pathways that regulate gene expression 
(Feng and Derynck, 2005). TGF-β inhibits epithelial cell 
growth, acting as a tumor suppressor, but it also promotes car-
cinoma progression and metastasis (Roberts and Wakefi  eld, 
2003). The tumor-promoting effects of TGF-β are based on 
its ability to induce (a) EMT, matrix invasiveness, and blood 
vessel intravasation by carcinoma cells (Huber et al., 2005); 
(b) cytostatic effects on surveilling immune cells (Li et al., 2006); 
and (c) proangiogenic effects (Bhowmick and Moses, 2005). 
TGF-β elicits EMT and in vivo metastasis via Smads and com-
plementary non-Smad effectors, such as Rho GTPases and p38 
MAPK (Moustakas and Heldin, 2005). TGF-β represses in-
hibitor of differentiation (Id) 2 and 3 expression and induces 
expression of the Notch ligand Jagged-1, which are critical 
events during EMT (Kondo et al., 2004; Kowanetz et al., 2004; 
  Zavadil et al., 2004). 
Here, we describe the role of high mobility group (HMG) 
A2, also known as HMGI-C, as an effector of TGF-β that causes 
EMT. HMGA2 and -1 constitute a family of nuclear factors that 
bind AT-rich DNA sequences (Reeves, 2001; Sgarra et al., 
2004). HMGA factors contribute to transcriptional regulation 
by organizing nucleoprotein complexes such as enhanceosomes 
(Merika and Thanos, 2001). HMGA2 is expressed during em-
bryogenesis and becomes silent in adult tissues (Sgarra et al., 
2004). However, HMGA2 is abundantly expressed by trans-
formed cells or tumors of mesenchymal and epithelial origin 
(for reviews see Reeves, 2001; Sgarra et al., 2004). In contrast, 
depletion of HMGA2 by antisense cDNA in thyroid cells elimi-
nates their transformation by myeloproliferative and Kirsten 
murine sarcoma viruses (Berlingieri et al., 1995). Here, we 
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pithelial–mesenchymal transition (EMT) occurs dur-
ing embryogenesis, carcinoma invasiveness, and 
metastasis and can be elicited by transforming 
growth factor-β (TGF-β) signaling via intracellular Smad 
transducers. The molecular mechanisms that control the 
onset of EMT remain largely unexplored. Transcriptomic 
analysis revealed that the high mobility group A2 
(HMGA2) gene is induced by the Smad pathway during 
EMT. Endogenous HMGA2 mediates EMT by TGF-β, 
whereas ectopic HMGA2 causes irreversible EMT char-
acterized by severe E-cadherin suppression. HMGA2 
provides transcriptional input for the expression control of 
four known regulators of EMT, the zinc-ﬁ  nger  proteins 
Snail and Slug, the basic helix-loop-helix protein Twist, 
and inhibitor of differentiation 2. We delineate a pathway 
that links TGF-β signaling to the control of epithelial dif-
ferentiation via HMGA2 and a cohort of major regulators 
of tumor invasiveness and metastasis. This network of 
  signaling/transcription factors that work sequentially to 
establish EMT suggests that combinatorial detection of 
these proteins could serve as a new tool for EMT analysis 
in cancer patients.
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show that HMGA2 regulates the transcription factors Snail, 
Slug, Twist, and Id2, thus linking TGF-β signaling to regulators 
of tumor invasiveness and metastasis. 
Results and discussion
TGF-𝗃/Smad signaling induces 
Hmga2 transcription
Transcriptomic analysis of TGF-β–induced EMT in mammary 
epithelial NMuMG cells identifi  ed Hmga2 as a prominent TGF-β 
target (Valcourt et al., 2005). Hmga2 mRNA increased after 2 
and 8 h and returned to basal levels after 36 h of TGF-β stimulation 
(Fig. 1 A). In contrast, Hmga1 mRNA was not regulated and 
dropped signifi  cantly upon cell confl  uence at 36 h (Fig. 1 A). 
HMGA2 protein increased after 8 h and peaked at 12 h of 
TGF-β stimulation (Fig. 1 B). A TGF-β type I receptor kinase 
inhibitor (LY580276; Peng et al., 2005) did not affect basal 
HMGA2 levels, demonstrating the absence of autocrine TGF-β 
(Fig. 1 B). Hmga2 mRNA induction by TGF-β was not im-
paired by the protein synthesis inhibitor cycloheximide while it 
was blocked by the RNA polymerase inhibitor II actinomycin D 
(Fig. S1 A, available at http://www.jcb.org/cgi/content/full/
jcb.200512110/DC1). A constitutively active form of the TGF-β 
type I receptor increased Hmga2 expression more effi  ciently 
than TGF-β itself, whereas a kinase-dead mutant of this recep-
tor inhibited it (Fig. S1 B). When the constitutively active type I 
receptor was expressed at higher levels, it often failed to in-
duce Hmga2 at higher levels than TGF-β (Valcourt et al., 2005). 
This refl  ects mechanisms of pathway desensitization, as TGF-β 
signaling is controlled in a timed fashion by activation and 
Figure 1. TGF-𝗃/Smad signaling induces 
Hmga2 transcription. (A) RT-PCR analysis of 
Hmga2 and Hmga1 expression in NMuMG 
cells stimulated with 5 ng/ml TGF-β for the 
indicated times. (B) Immunoblot analysis of 
endogenous Hmga2 in NMuMG cells treated 
with vehicle (0), TGF-β type I receptor inhibi-
tor LY580276 (2.5 μM; LY) for 4 h, or stimu-
lated with TGF-β for the indicated periods of 
time. Histone H1 serves as a loading control. 
  Molecular mass markers are in bp (A) and 
kD (B). (C) Hmga2 promoter assays of the 
indicated deletion constructs in HepG2 cells 
stimulated (gray bars) or not (white bars) with 
5 ng/ml TGF-β for 24 h. The black box in the 
Hmga2 promoter corresponds to a TCC repeat-
rich sequence. (D) Quantitative RT-PCR analy-
sis of Hmga2 expression in NMuMG clones 
expressing dominant-negative Smad2 (S2 SA) 
or empty vector (mock) induced or not with 
10 μM CdCl2 for 24 h, before stimulation with 
5 ng/ml TGF-β for 4 h. (E) Promoter assays of 
the Hmga2 BaP construct in HepG2 cells trans-
fected with Smad2 SA and stimulated (gray 
bars) or not (white bars) with 5 ng/ml TGF-β for 
24 h. (F and G) Quantitative RT-PCR analysis 
of Hmga2 expression in NMuMG (F) and MDA-
MB-231 (G) clones expressing short hairpin
vectors (sh-Smad) directed against Smad2, -3, 
and -4, or the empty vector and treated with 
5 ng/ml TGF-β for 6 h. Asterisks indicate statis-
tically signiﬁ  cant gene expression or promoter 
activity differences between TGF-β–stimulated 
and nonstimulated conditions (P < 0.05). 
(H) ChIP assays in NMuMG cells treated or 
not with 5 ng/ml TGF-β for 2 h using a Smad4 
antibody or a preimmune serum (Ctrl) and am-
pliﬁ  cation of Hmga2 promoter fragments. HMGA2 MEDIATES EMT BY TGF-β • THUAULT ET AL. 177
  inactivation of receptor and Smads. The results suggest that 
Hmga2 is a direct TGF-β target. 
Mouse Hmga2 promoter analysis showed that basal pro-
moter activity varied according to the deletion construct used, 
and TGF-β stimulation led to a 2.5–3-fold induction (Fig. 1 C). 
Basal promoter activity and induction by TGF-β were lost 
when the proximal region containing TCC repeats was deleted. 
  Sequence inspection of 4 kbp upstream from the transcription 
initiation site showed few noncanonical Smad binding elements 
between −700 and −100 bp (unpublished data). We now exam-
ine the role of these elements on Hmga2 transcriptional induc-
tion by TGF-β. 
Hmga2 mRNA induction and promoter activation by 
TGF-β was blocked in cells expressing dominant-negative 
Smad2 (Smad2 SA; Fig. 1, D and E); Smad2 SA cannot be 
phosphorylated by the TGF-β type I receptor and blocks TGF-β–
induced EMT (Valcourt et al., 2005). Knockdown of Smad2 
by 80% or Smad3 by 65% after RNAi had no effect on Hmga2 
induction by TGF-β or on the EMT response (Fig. 1 F and Fig. 
S1, C and D). However, knockdown of the common partner of 
Smad2 and -3, Smad4, by 95% effectively blocked Hmga2 in-
duction by TGF-β and the EMT response (Fig. 1 F and Fig. S1, 
C and D; Deckers et al., 2006). The lack of effect by knockdown 
of Smad2 or -3 may indicate that the protein depletion achieved 
was insuffi  cient. Alternatively, both Smad2 and -3 may be in-
volved in EMT, as we previously proposed (Valcourt et al., 
2005), and for effective block of EMT, both Smad2 and -3 need 
to be depleted. Experiments are under way to test this   possibility. 
In another cell line, metastatic breast cancer MDA-MB-231 
cells, TGF-β weakly induced HMGA2 expression, and knock-
down of Smad3 or -4 blocked this response, whereas knock-
down of Smad2 did not (Fig. 1 G and Fig. S1, E and F). Based 
on these data, it appears that single Smad3 or -4 knockdown is 
suffi  cient in blocking TGF-β–induced HMGA2 expression (Fig. 
1 G and Fig. S1 F). A more robust knockdown of Smad2 is 
needed to reach fi  nal conclusions about the role of this Smad 
isoform in HMGA2 regulation and EMT. 
Finally, immunoprecipitation of chromatin bound Smad4 
from NMuMG cells confi  rmed a TGF-β–inducible association of 
Smad4 in the proximal (−195/+5) and upstream (−495/+245) 
but not in the distal (−3420/−3320) promoter region of the 
Hmga2 gene (Fig. 1 H). The −500 to +5 Hmga2 promoter re-
gion where Smad4 binds overlapped with putative Smad binding 
elements. The results establish that Smad signaling is involved in 
Hmga2 induction by TGF-β, with Smad4 clearly being implicated. 
However, we cannot conclude whether Smad4 cooperates with 
Smad2, Smad3, or both during Hmga2 regulation.
Ectopic HMGA2 weakly inhibits epithelial 
cell proliferation
To address the functional role of HMGA2, we established stable 
NMuMG clones inducibly expressing human HMGA2. Ectopic 
HMGA2 was expressed in the absence of an inducer, and in-
duction increased its expression further (Fig. 2 A). Ectopic 
HMGA2 localized in the nucleus as expected, and its localiza-
tion was not affected by TGF-β (Fig. 2 B). In the absence of 
TGF-β, HMGA2 clones grew slower than mock cells (Fig. 2 C). 
TGF-β inhibited growth of mock and HMGA2-expressing cells 
(Fig. 2 D). Thus, TGF-β induces growth arrest despite ectopic 
HMGA2 expression.
HMGA2 mediates EMT in response to TGF-𝗃
Mock NMuMG clones treated with an inducer displayed char-
acteristic polarized epithelial morphology (Fig. 3 A). TGF-β 
caused EMT, as mock cells acquired elongated, fi  broblast-like 
morphology. HMGA2 clones were constitutively elongated and 
lost cell–cell contacts, suggesting induction of EMT, which was 
enhanced further by TGF-β (Fig. 3 A). EMT in HMGA2 clones 
was confi  rmed by visualizing actin cytoskeleton rearrangements 
and the loss of ZO-1 and E-cadherin from cell junctions (Fig. 3 B) 
and by measuring the loss of expression of E-cadherin and 
  Mucin-1 mRNA (Fig. 3 C). Moreover, mRNAs of the mesen-
chymal markers PAI-1, Timp-3, and Fibronectin-1 were consti-
tutively expressed, and Vimentin was increased to a lesser extent. 
Immunoblot analysis confi  rmed E-cadherin protein down-
  regulation and enhanced expression of mesenchymal N-  cadherin 
in HMGA2 clones (Fig. 3 D). These experiments demonstrate 
that ectopic HMGA2 causes EMT.
The fact that ectopic HMGA2 mimicked the TGF-β re-
sponse (Fig. 3, C and D) raises the question of whether HMGA2 
Figure 2.  HMGA2 inhibits cell proliferation. (A) Analysis of ectopic 
HMGA2 expression in NMuMG clones (mock, 5, and 13) transfected with 
empty or HMGA2 vector. Cells were stimulated with 5 ng/ml TGF-β for 
36 h, 24 h after induction with 10 μM CdCl2. Immunoblots were incu-
bated with anti-HA antibody. β-Tubulin is loading control. Molecular mass 
markers are in kD. (B) Immunostaining with anti-HA antibody of mock 
NMuMG and HMGA2 clone 5 stimulated with 5 ng/ml TGF-β for 36 h. 
Bar, 10 μm. (C) Cell proliferation assays with mock (diamonds) and 
HMGA2 clones (5, squares; 13, triangles). (D) Cell proliferation assays 
with mock and HMGA2 clones 5 and 13 stimulated (gray bars) or not 
(white bars) with TGF-β for 4 d.JCB • VOLUME 174 • NUMBER 2 • 2006  178
activates autocrine TGF-β, leading to EMT. In mock NMuMG 
cells, the LY580276 inhibitor blocked TGF-β–mediated EMT, 
as cells kept a cortical actin distribution and did not down-
  regulate E-cadherin (Fig. S2, available at http://www.jcb.org/
cgi/content/full/jcb.200512110/DC1). However, in HMGA2 
clones, LY580276 had no effect on the elongated morphology, 
actin stress fi  ber network, or lack of E-cadherin. Similar results 
were obtained with a TGF-β–neutralizing antibody added to the 
medium of HMGA2 clones for several days (unpublished data). 
These experiments demonstrate that the profound effects 
HMGA2 shows on EMT cannot be accounted for by the induc-
tion of autocrine TGF-β that signals in a constitutive manner.
Transfection of NMuMG cells with Hmga2 siRNA re-
sulted in an  70% decrease in basal and TGF-β–induced Hmga2 
mRNA expression (Fig. 4 A). An even stronger reduction was 
seen of the endogenous HMGA2 protein level (Fig. S3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200512110/DC1).
Weak nuclear HMGA2 was seen in control cells; TGF-β dra-
matically increased the nuclear HMGA2 levels, as the cells 
became elongated and fi  broblast like (Fig. S3). Upon HMGA2 
depletion, its nuclear staining was barely detectable. Immuno-
blot analysis of endogenous HMGA2 protein upon chromatin 
extraction (Fig. 1 B) was not effi  cient enough in these transfected 
cells to quantitatively monitor the degree of protein depletion 
upon RNAi (unpublished data). We reproducibly observed that 
the mammary epithelial cells enlarged their diameter by roughly 
1.8–2.2-fold when HMGA2 was depleted (Fig. S3). This effect 
was specifi  c for the Hmga2 siRNA, as we did not observe size 
changes by control (siLuc) or a panel of siRNAs that target un-
related genes in this cell line (Fig. S3 and unpublished data).
Figure 3.  HMGA2 induces EMT. (A) Phase-
contrast microscopy of mock and HMGA2 
clones. HMGA2 induction with 10 μM CdCl2 
was followed by vehicle (control) or 5 ng/ml 
TGF-β stimulation for 36 h. (B) Visualization of 
actin cytoskeleton and the epithelial markers 
ZO-1 and E-cadherin by immunostaining of 
mock and HMGA2 clones treated with vehicle 
(control) or 5 ng/ml TGF-β for 36 h. Bars, 
10 μm. (C) RT-PCR analysis of EMT markers. 
HMGA2 clones were treated as in A. Parental 
NMuMG cells were treated with 5 ng/ml TGF-β 
for 36 h. (D) Immunoblot analysis of E- and 
N-cadherin in cells treated as in A. Molecular 
mass markers are in bp (C) and kD (D).HMGA2 MEDIATES EMT BY TGF-β • THUAULT ET AL. 179
TGF-β induced EMT in NMuMG cells transfected with 
  control siRNA. In contrast, cells transfected with Hmga2 siRNA 
do not undergo EMT. Indeed, these cells maintained polarized 
morphology, ZO-1, and E-cadherin at their junctions and decreased 
the TGF-β–inducible levels of N-cadherin and   Fibronectin-1 
(Fig. 4, B–E; and Fig. S3). Although Hmga2 knockdown restored 
to a large extent epithelial tight and adherence junctions, we ob-
served only a weak block of total ZO-1 and E-cadherin protein 
down-regulation by TGF-β (unpublished data). We conclude that 
endogenous HMGA2 is required for TGF-β–induced EMT. 
HMGA2 regulates expression of key 
regulators of EMT
The zinc-fi  nger transcription factors Snail, Slug, δEF-1/ZEB-1, 
and SIP-1/ZEB-2 or the basic helix-loop-helix factor Twist re-
press E-cadherin expression during embryonic EMT (Peinado 
et al., 2004) and promote tumor cell metastasis or cancer recur-
rence after therapy (Yang et al., 2004; Moody et al., 2005). 
The extreme down-regulation of E-cadherin expression in 
HMGA2 clones (Fig. 3, C and D) prompted us to analyze some 
of these transcriptional repressors. In parental NMuMG cells, 
Snail and Slug and, to a lesser extent, Twist mRNA were  induced 
by TGF-β (Fig. 5, A and C). Repressor expression was dramati-
cally up-regulated in HMGA2 clones even in the absence of 
TGF-β. Similar to regulation of endogenous Snail and Twist 
mRNA, TGF-β induced Snail and Twist promoter activity 
(Fig. 5 B). Notably, cotransfection of HMGA2 enhanced Snail and 
Twist promoter activity to signifi  cantly higher levels than TGF-β 
stimulation alone. As specifi  city control, the Smad3/Smad4-
  dependent promoter reporter CAGA12-Luc was not regulated by 
HMGA2 (unpublished data). Upon RNAi-mediated knockdown 
of Hmga2, endogenous Snail mRNA induction by TGF-β was 
reduced by  50% (Fig. 5 D). This explains why total E- cadherin 
and ZO-1 protein levels were still repressible by TGF-β after 
Hmga2 knockdown (unpublished data). We conclude that par-
tial depletion of endogenous Hmga2 by RNAi is suffi  cient to 
Figure 4.  HMGA2 mediates EMT by TGF-𝗃. 
(A) Quantitative RT-PCR analysis of Hmga2 ex-
pression in NMuMG cells transfected with 
  control (siLuc) or speciﬁ  c siRNA against Hmga2 
(siHmga2) and treated with vehicle (white 
bars) or 5 ng/ml TGF-β (gray bars) for 12 h. 
(B) Phase-contrast images. (C) Indirect immuno-
ﬂ   uorescence of ZO-1 and E-cadherin. Bars, 
10 μm. (D) Immunoblot analysis of N-cadherin 
in NMuMG cells transfected as in A and 
treated with vehicle (control) or 5 ng/ml TGF-β 
for 36 h. β-Tubulin is loading control.  Molecular 
mass markers are in kD. (E) Quantitative 
RT-PCR analysis of Fibronectin-1 (FN1) expres-
sion in cells treated as in A. Asterisks indicate 
statistically signiﬁ  cant gene expression differ-
ences compared with the ground condition 
(P < 0.05). JCB • VOLUME 174 • NUMBER 2 • 2006  180
  restore epithelial differentiation in NMuMG cells and establish-
ment of cell–cell junctions; however, it is not suffi  cient to block 
strongly enough Snail induction by TGF-β.
TGF-β down-regulates Id2 to induce EMT (Kondo et al., 
2004; Kowanetz et al., 2004). Id2 mRNA and protein expres-
sion were down-regulated in HMGA2 clones compared with 
mock cells, and TGF-β further repressed Id2 levels (Fig. 5, 
E and F). The results demonstrate that HMGA2 regulates Snail, 
Slug, Twist, and Id2, all key players of EMT. TGF-β induces 
Snail expression either via Smad3 or via MAPK signaling 
  (Peinado et al., 2003; Saika et al., 2004). Our results add 
HMGA2 as a novel regulator of Snail expression downstream 
of Smads. Whether HMGA2 cooperates with Smad3 or MAPK 
signals to induce Snail is being explored. Twist is another gene 
target of HMGA2 that is weakly induced by TGF-β. We 
 conclude  that  TGF-β, via HMGA2, primarily affects the Snail 
pathway and, to a lesser extent, the Twist pathway.
Concluding remarks
We describe a new target of TGF-β signaling, the nuclear factor 
HMGA2, and a new transcriptional circuitry that mediates EMT 
by TGF-β (Fig. 5 G). HMGA2 links TGF-β signaling to major 
factors of tumor invasiveness and metastasis. This work sug-
gests that HMGA2 acts not only as an architectural chromatin 
factor as previously thought but also as a gene-specifi  c regulator 
that responds to signals from extracellular factors.
HMGA2 is overexpressed in a variety of tumors primarily 
of mesenchymal origin (for review see Sgarra et al., 2004). 
However, the mechanism of HMGA2 action is not yet known. 
This study demonstrates for the fi  rst time that HMGA2 is in-
volved in EMT. Our results are consistent with the specifi  c pres-
ence of HMGA2 at the invasive front of squamous carcinomas 
(Miyazawa et al., 2004), a place where EMT occurs during 
  cancer progression. On the other hand, overexpression in MCF7 
mammary carcinoma cells of HMGA1b, another member of 
the HMGA family, but not that of the related HMGA1a, led to 
invasive tumor growth in nude mice (Reeves et al., 2001). 
  Histochemical and transcriptomic analysis of tumor samples 
from such mice indicated that HMGA1b induced expression of 
genes with links to EMT.
Our study demonstrates that HMGA2 is necessary and 
suffi  cient for TGF-β–induced EMT. Considering the variety of 
Figure 5.  HMGA2 regulates expression of 
key regulators of EMT. (A) Quantitative RT-PCR 
analysis of Snail and Twist expression in pa-
rental or HMGA2 clones stimulated (gray bars) 
or not (white bars) with 5 ng/ml TGF-β for 36 h. 
(B) Luciferase reporter assays of Snail and 
Twist promoter constructs in HepG2 cells trans-
fected with mock (−) or HA-hHMGA2 (+) vec-
tor and treated with 5 ng/ml TGF-β for 24 h. 
(C) Quantitative RT-PCR analysis of Slug ex-
pression under conditions as in A. (D) Quanti-
tative RT-PCR analysis of Snail expression in 
NMuMG cells transfected with control (siLuc) 
or Hmga2 (siHmga2) siRNA and treated with 
vehicle (white bars) or 5 ng/ml TGF-β (gray 
bars) for 12 h. Asterisks indicate statistically 
signiﬁ  cant gene expression or promoter activ-
ity differences compared with the ground con-
dition (P < 0.05). Expression pattern of Id2 
using RT-PCR (E) or protein (F) analysis in mock 
and HMGA2 clones induced with 10 μM 
CdCl2 24 h before stimulation with 5 ng/ml 
TGF-β for 36 h. Molecular mass markers are in 
bp (E) and kD (F). (G) Diagram of the role of 
HMGA2 in TGF-β–induced EMT.HMGA2 MEDIATES EMT BY TGF-β • THUAULT ET AL. 181
tumors where HMGA2 expression has been detected, it will be 
interesting to determine in how many of them TGF-β is the 
  upstream inducer of tumor HMGA2 expression and to what 
  extent the signaling network outlined here explains the tumor-
promoting properties of TGF-β.
Materials and methods
Cells, adenoviruses, and reagents
Mouse mammary epithelial NMuMG, human hepatocarcinoma HepG2, 
human MDA-MB-231-Eco cells, and stable NMuMG clones expressing 
Smad2 SA (mutant with alanines in place of two C-terminal serines that be-
come phosphorylated by receptors) have been described (Kowanetz et al., 
2004; Valcourt et al., 2005; Deckers et al., 2006). Adenoviruses express-
ing control GFP (Ad-GFP) were a gift from B. Vogelstein (Johns Hopkins 
Medical Institutions, Baltimore, MD); adenoviruses expressing C-terminally 
HA-tagged constitutively active TGF-β type I receptor (activin receptor-like 
kinase 5) ALK-5(TD) and HA-tagged kinase-inactive ALK5(KR) receptor 
were a gift from K. Miyazono (University of Tokyo, Tokyo, Japan) and have 
been described (Valcourt et al., 2005). 
The mouse Hmga2 siRNA (available from GenBank/EMBL/DDBJ 
under accession no. NM_010441), which was a single RNA oligonucle-
otide (D-043585-03), and control siRNA against the luciferase reporter 
vector pGL2 (accession no. X65324) were obtained from Dharmacon 
  Research, Inc. Human HMGA2 cDNA, cloned by PCR from total normal 
human mRNA in pcDNA3-HA C-terminally of the HA tag using EcoRI–XhoI 
as restriction sites, resulted in pcDNA3-HA-hHMGA2. The N-terminally 
HA-tagged hHMGA2 HindIII–XhoI fragment was subcloned in the inducible 
vector pMEP4 to produce pMEP4-HA-hHMGA2.
The LY580276 inhibitor for the TGF-β type I receptor kinase was a gift 
from J.M. Yingling (Eli Lilly and Company, Indianapolis, IN; Peng et al., 
2005). Recombinant mature TGF-β1 was obtained from PeproTech and 
TGF-β3 from K.K. Iwata (OSI Pharmaceuticals, Farmingdale, NY). TGF-β1 
was used in most experiments and TGF-β3 in experiments with stable NMuMG 
and MDA-MB-231 clones for Smad shRNAs (Fig. 1 and Fig. S1). TGF-β1 and 
-β3 have indistinguishable effects on EMT or Hmga2 gene regulation.
Cell counting
Cell monolayers were washed with PBS, trypsinized, and resuspended in PBS, 
and cell numbers were calculated using a Z1 cell counter (Beckman Coulter). 
Numbers are plotted as means from triplicate determinations with stan-
dard errors.
Cell transfections
pMEP4 and pMEP4-HA-hHMGA2 were transfected into NMuMG using 
  Lipofectamine 2000 (Invitrogen). 2 d after transfection, cells were cultured in 
400 μg/ml hygromycin-B (Calbiochem), and individual antibiotic-resistant 
clones were derived. For HMGA2 induction, cells growing in hygromycin-B 
were treated with 10 μM CdCl2 (Sigma-Aldrich) for 24 h, and cells were 
incubated with vehicle or TGF-β for another 24–48 h.
NMuMG cells were transiently transfected with Hmga2 siRNAs using 
Dharmafect 4 (Dharmacon Research, Inc.). After 2 h of stimulation with 
TGF-β, cells were retransfected with siRNAs to a ﬁ  nal  concentration  of 
50 nM for 10 h (RNA assay) or 36 h (protein/immunoﬂ  uorescence assay).
NMuMG and MDA-MB-231-Eco clones with Smad knockdown were 
established after infection with retroviral supernatants derived from cells 
transfected with pRetroSuper-expressing shRNA against Smad2, -3, or -4 
and were provided by M. van Dinther and P. ten Dijke (Leiden University 
Medical Center, Leiden, Netherlands; Deckers et al., 2006). The shRNA 
  oligonucleotide sequences were 5′- G  G  A  G  T  G  C  G  C  T  T  G  T  A  T  T  A  C  A  -3′ (mouse/
human Smad2), 5′-C  G  T  C  A  A  C  A  C  C  A  A  G  T  G  C  A  T  C  -3′ (mouse/human Smad3), 
and 5′- C  C  A  G  C  T  A  C  T  T  A  C  C  A  T  C  A  T  A  -3′ (mouse/human Smad4).
RT-PCR
Total DNA-free cellular RNA was extracted with the RNeasy kit (QIAGEN). 
RT-PCRs were performed as described previously (Kowanetz et al., 2004) 
and analyzed using speciﬁ  c primers (Tables I and II). Primers for mouse 
glyceraldehyde-3′-phosphate dehydrogenase ( Gapdh) were used for 
  reference. Lack of DNA contamination was veriﬁ  ed by omitting reverse 
transcriptase (−RT). Quantitative real-time PCR reactions were done as 
  described previously (Valcourt et al., 2005). Gene expression levels were 
determined with the comparative Ct method using Gapdh as reference. 
The ground condition was set to 1, and expression data are presented as 
bar graphs of mean values plus standard deviations.
Perchlorate extraction of chromatin
NMuMG cells were lysed in 140 mM NaCl, 1.5 mM MgCl2, 10 mM Tris- 
HCl, pH 8.6, and 0.5% NP-40, supplemented with protease inhibitors. 
After centrifugation (3 min, 6,000 g, 4°C), nuclear pellets were resus-
pended, vortexed for 30 s, and rotated at room temperature for 1 h in 5% 
perchloric acid. Perchloric acid supernatants (5 min, 6,000 g, 25°C) were 
precipitated by 8 vol cold ethanol and centrifuged (15 min, 10,000 g, 
Table I. Oligonucleotide primers used for semiquantitative RT-PCR analysis of mouse and human genes
Gene Primer sequence Strand Product size Temperature PCR cycle Reference
bp °C
Id2 5′-G  C  A  T  C  C  C  C  C  A  G  A  A  C  A  A  G  A  A  G  G  T  -3′
5′-C  C  A  G  G  C  C  G  G  A  G  A  A  C  A  A  G  A  C  A  C  -3′
+
−
451 57 28 Kowanetz et al., 2004
Timp3 5′-C  T  C  C  T  G  T  T  G  C  C  C  A  G  G  A  T  A  G  C  -3′
5′-C  T  C  T  C  T  C  T  C  C  T  G  C  C  T  T  C  T  C  C  -3′
+
−
350 60 28 Valcourt et al., 2005
PAI-1 5′-G  G  G  A  A  A  A  G  G  G  G  C  T  G  T  G  T  G  A  C  -3′
5′-G  T  A  C  A  C  G  G  T  G  T  G  T  G  G  C  T  G  T  C  -3′
+
−
406 57 27 M33960
Mucin1 5′-G  A  T  G  C  A  G  T  T  C  C  C  T  C  C  C  T  C  T  G  -3′
5′-C  C  T  A  C  C  A  G  A  A  G  T  C  C  T  G  G  C  T  C  -3′
+
−
450 60 25 Valcourt et al., 2005
Hmga2 5′-AACCTTACTGGGTCGGCATC-3′
5′-GGTGAGGTTTGAGCTCCTTC-3′
+
−
419 58 25 Valcourt et al., 2005
HMGA2 5′-G  G  G  C  C  A  G  G  A  G  G  T  A  G  T  T  T  C  T  C  -3′
5′-C  C  T  C  G  G  T  G  C  A  C  C  A  T  G  T  T  T  G  G  C  -3′
+
−
321 60 24 NM_003483
Hmga1(a/b) 5′-C  C  C  A  G  T  G  A  A  G  T  G  C  C  A  A  C  T  C  C  G  -3′
5′-C  C  T  C  A  G  A  G  G  A  C  T  C  C  T  G  G  G  A  G  A  -3′
+
−
171 60 24 NM_016660
NM_001025427
E-cadherin 5′-G  T  C  A  G  A  T  C  T  C  C  C  T  G  A  G  T  T  C  G  -3′
5′-G  C  A  C  C  C  A  C  A  C  A  C  A  T  A  C  A  C  T  C  -3′
+
−
391 56 27 NM_009864
Vimentin 5′-G  A  A  G  G  A  A  G  A  G  A  T  G  G  C  T  C  G  T  C  -3′
5′-C  T  G  C  A  C  T  G  T  T  G  C  A  C  C  A  A  G  T  G  -3′
+
−
315 57 25 NM_011701
Fibronectin-1 5′-C  C  C  A  G  A  C  T  T  A  T  G  G  T  G  G  C  A  A  T  T  C  -3′
5′-A  A  T  T  T  C  C  G  C  C  T  C  G  A  G  T  C  T  G  A  -3′
+
−
200 60 26 NM_010233
Gapdh/GAPDH 5′-A  T  C  A  C  T  G  C  C  A  C  C  C  A  G  A  A  G  A  C  -3′
5′-A  T  G  A  G  G  T  C  C  A  C  C  A  C  C  C  T  G  T  T  -3′
+
−
443 57 30 Valcourt et al., 2005
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4°C), and pellets were resuspended in lysis buffer and analyzed by 
immunoblotting.
Immunoblotting and immunoﬂ  uorescence microscopy
Total protein extracts subjected to SDS-PAGE were analyzed by immuno-
blotting as described previously (Kowanetz et al., 2004). Mouse monoclo-
nal anti–β-tubulin (T8535) and anti–β-actin (AC-15) were obtained from 
Sigma-Aldrich; mouse monoclonal anti-HA (12CA5) was obtained from 
Roche Applied Science; mouse monoclonal anti–E-cadherin (C20820) 
was obtained from BD Biosciences; rat monoclonal anti–ZO-1 (MAB1520) 
was obtained from Chemicon; and mouse monoclonal anti–histone H1 
(AE-4), anti-Smad2/Smad3 (H-2), and anti-Smad4 (B-8) were obtained 
from Santa Cruz Biotechnology, Inc. Rabbit polyclonal anti-Hmga2 was 
raised against a synthetic peptide (C  S  P  S  K  A  A  Q  K  K  A  E  T  I  G  E  , where S maps 
at residue 59 of mouse Hmga2) and recognizes mouse but not human 
HMGA2. Secondary anti–mouse IgG and anti–rabbit IgG coupled to 
horseradish peroxidase were purchased from GE Healthcare. The en-
hanced chemiluminescence detection system was purchased from Santa 
Cruz Biotechnology, Inc.
For immunoﬂ  uorescence, cells were treated as indicated in the ﬁ  g-
ure legends, ﬁ  xed, and stained with tetramethyl-rhodamine isothiocyanate 
(TRITC)–labeled phalloidin (Sigma-Aldrich) or with rat anti–ZO-1, mouse 
anti–E-cadherin, and rabbit anti-HMGA2 antibodies as primary antibodies 
and TRITC-conjugated goat anti–rat IgG and FITC-conjugated anti–mouse 
or anti–rabbit IgG antibodies as secondary antibodies (Jackson Immuno-
Research Laboratories) as described previously (Kowanetz et al., 2004). 
Photomicrographs were obtained by a microscope (Axioplan 2; Carl Zeiss 
MicroImaging, Inc.) with a digital camera (C4742-95; Hamamatsu), using 
Plan-neoﬂ  uar  40×/0.75 objective lens (Carl Zeiss MicroImaging, Inc.) 
and photographing at ambient temperature in the absence of oil   immersion. 
Primary images were acquired with the camera’s QED software. Image 
memory content was reduced, and brightness contrast was adjusted using 
Photoshop 6.0 (Adobe).
Promoter-reporter assays
HepG2 cells were transiently transfected with calcium phosphate and a 
panel of mouse Hmga2 promoter luciferase constructs as described previ-
ously (Rustighi et al., 1999). The Snail and Twist promoter luciferase con-
structs were provided by A. Cano (Universidad Autónoma de Madrid, 
Madrid, Spain) and L.R. Howe (Cornell University, New York, NY), respec-
tively. All promoter constructs were cotransfected with the normalization 
  reporter plasmid pCMV–β-Gal and the expression vector pcDNA3 (mock 
vector) or pcDNA3-HA-hHMGA2 for Snail and Twist promoter analysis or 
pcDNA3-HA-Smad2 SA for Hmga2 promoter analysis. The enhanced lucif-
erase assay kit from BD Biosciences was used. Normalized promoter activ-
ity data are plotted in bar graphs representing mean values from triplicate 
determinations with standard deviations. Each independent experiment 
was repeated at least twice.
Chromatin immunoprecipitation (ChIP) assays
The equivalent of 10
7 cells was used per ChIP reaction. Cross-linking was 
performed using 1% formaldehyde followed by neutralization with 0.125 
M glycine. Cells were lysed in 1% SDS, 10 mM EDTA, 50 mM Tris, pH 
8.1, and protease inhibitors on ice. DNA was sheared by sonication to 
200–1,000 bp in length. Sonicated cell pellets were diluted 10 times in 
a buffer containing 0.01% SDS and were precleared with protein A–
  Sepharose in the presence of BSA and salmon sperm DNA before incubation 
with 5 μg rabbit anti-Smad4 antibody (H-552; Santa Cruz Biotechnology, 
Inc.) or preimmune rabbit antiserum as a negative control. Protein–DNA 
complexes were precipitated with protein A–Sepharose in the presence of 
BSA and salmon sperm DNA. Immunoprecipitated complexes were washed 
once with 150 mM NaCl, 0.2% SDS, 1% Triton X-100, 2 mM EDTA, and 
20 mM Tris-HCl, pH 8.1; once with an identical buffer containing 500 mM 
NaCl; once with 0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 
and 10 mM Tris-HCl, pH 8.1; and twice with 10 mM Tris-EDTA. 
  Immunoprecipitated complexes were eluted with 1% SDS and 0.1 M NaHCO3. 
After reversal of cross-links by heating in 0.2 M NaCl, proteinase K 
Table II. Oligonucleotide primers used for quantitative RT-PCR and ChIP
Gene Primer sequence Strand Product size Reference
bp
Oligonucleotide primers used for quantitative 
 real-time RT-PCR analysis of mouse genes
  PAI-1 5′-G  G  G  A  A  A  A  G  G  G  G  C  T  G  T  G  T  G  A  C  -3′ 
5′-G  T  A  C  A  C  G  G  T  G  T  G  T  G  G  C  T  G  T  C  -3′
+
−
406 M33960
  Snail 5′-A  C  C  C  C  C  G  C  C  G  G  A  A  G  C  C  C  A  A  C  T  -3′
5′-A  G  C  G  G  C  G  G  G  G  T  T  G  A  G  G  A  C  C  T  C  -3′
+
−
127 NM_011427
  Slug 5′-C  T  C  A  C  C  T  C  G  G  G  A  G  C  A  T  A  C  A  G  C  -3′
5′-T  G  A  A  G  T  G  T  C  A  G  A  G  G  A  A  G  G  C  G  G  G  -3′
+
−
146 NM_011415
  Twist 5′-C  G  G  G  T  C  A  T  G  G  C  T  A  A  C  G  T  G  -3′
5′-C  A  G  C  T  T  G  C  C  A  T  C  T  T  G  G  A  G  T  C  -3′
+
−
196 NM_011658
  Hmga2 5′-A  G  C  A  A  A  A  A  C  A  A  G  A  G  C  C  C  C  T  C  T  A  -3′
5′-A  C  G  A  C  T  T  G  T  T  G  T  G  G  C  C  A  T  T  T  C  -3′
+
−
100 NM_010441
  Fibronectin-1 5′-C  C  C  A  G  A  C  T  T  A  T  G  G  T  G  G  C  A  A  T  T  C  -3′
5′-A  A  T  T  T  C  C  G  C  C  T  C  G  A  G  T  C  T  G  A  -3′
+
−
200 NM_010233
  Gapdh 5′-TGTGTCCGTCGTGGATCTGA-3′
5′-CCTGCTTCACCACCTTCTTGA-3′
+
−
76 NM_001001303
Oligonucleotide primers used for quantitative 
 real-time RT-PCR in human cells
  HMGA2 5′-C  C  C  A  A  A  G  G  C  A  G  C  A  A  A  A  A  C  A  A  -3′
5′-G  C  C  T  C  T  T  G  G  C  C  G  T  T  T  T  T  C  T  C  -3′
+
−
81 NM_003483
  GAPDH 5′-G  G  A  G  T  C  A  A  C  G  G  A  T  T  T  G  G  T  C  G  T  A  -3′
5′-G  G  C  A  A  C  A  A  T  A  T  C  C  A  C  T  T  T  A  C  C  A  G  A  G  T  -3′
+
−
78 BC023632
Oligonucleotide primers used to amplify 
 different regions of the Hmga2 promoter
  Hmga2 promoter −3420/−3320 5′-T  A  A  T  G  C  G  C  T  T  G  C  C  T  G  A  G  C  T  A  -3′
5′-G  C  T  G  T  C  A  A  A  T  C  G  G  G  C  A  T  C  A  -3′
+
−
100 AC153362
  Hmga2 promoter −495/−245 5′-T  C  C  T  G  G  C  A  G  A  A  A  C  T  T  C  C  A  C  T  C  T  -3′
5′-T  G  G  A  G  T  G  A  A  T  T  G  T  G  T  C  C  C  T  T  G  A  -3′
+
−
250 NM_010441
  Hmga2 promoter −194/+45 ′-G  A  G  C  C  T  T  T  G  C  G  G  A  G  A  G  A  G  C  A  A  -3′
5′-C  A  T  C  A  A  C  A  C  C  G  G  A  C  G  T  C  C  A  -3′
+
−
200 NM_010441HMGA2 MEDIATES EMT BY TGF-β • THUAULT ET AL. 183
  treatment, puriﬁ   cation by classical phenol-chloroform extraction, and 
  ethanol precipitation, DNA pellets were resuspended in 20 μl of water. 
  Input material before immunoprecipitation corresponds to one third of the 
immunoprecipitated material. Input DNA pellets were resuspended in 50 μl 
of water. PCR was performed using 2 μl of immunoprecipitated or 0.5 μl 
of input material using Taq DNA polymerase (Invitrogen). Ampliﬁ  cation 
was performed for 30 cycles for immunoprecipitated DNA and 25 cycles 
for input DNA. Primer sets used to amplify different regions of the Hmga2 
promoter are described in Table II.
Statistical analysis
Statistical analysis of real-time PCR quantiﬁ   cation and promoter assays 
was performed by two-tailed paired t test. Signiﬁ  cance was considered at 
P ≤ 0.05.
Online supplemental material
Fig. S1 demonstrates that Hmga2 is a direct gene target of TGF-β signaling 
and analyzes the effects of siRNA-mediated knockdown of Smads on 
EMT and Hmga2 expression. Fig. S2 demonstrates that ectopic HMGA2 
does not induce autocrine TGF-β signaling. Fig. S3 analyzes the effects 
of siRNA-mediated knockdown of Hmga2 on its endogenous protein 
level and localization. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200512110/DC1.
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